Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

15.34
-0.2400-1.54%
Post-market: 15.340.00000.00%19:35 EDT
Volume:1.19M
Turnover:18.38M
Market Cap:1.21B
PE:7.56
High:15.86
Open:15.58
Low:15.24
Close:15.58
52wk High:16.77
52wk Low:5.70
Shares:78.65M
Float Shares:70.64M
Volume Ratio:0.59
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.03
EPS(LYR):1.87
ROE:82.56%
ROA:2.29%
PB:5.20
PE(LYR):8.20

Loading ...

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody IND Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

GlobeNewswire
·
Aug 03

HENLIUS Receives NMPA Approval for Clinical Trial of HLX43 Combination Therapy in Advanced Solid Tumors

Stock News
·
Jul 31

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Completes Patient Enrollment in Phase II Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

GlobeNewswire
·
Jul 30

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

GlobeNewswire
·
Jul 28

Agilent receives EU approval for PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jul 23

PagerDuty price target raised to $8 from $7 at BofA

TIPRANKS
·
Jul 22

Pagerduty Cut to Underweight from Equal-weight by Morgan Stanley

Dow Jones
·
Jul 21

Morgan Stanley Downgrades PagerDuty to Underweight From Equalweight, Trims Price Target to $9 From $10

MT Newswires Live
·
Jul 21

Pagerduty, Inc. : Morgan Stanley Cuts to Underweight from Equal-weight

THOMSON REUTERS
·
Jul 21

PagerDuty downgraded to Underweight from Equal Weight at Morgan Stanley

TIPRANKS
·
Jul 21

Pagerduty Executive Chair Jennifer Tejada Sells USD 4.23 Million in Common Shares

Reuters
·
Jul 21

CStone Pharma's CS2009 Tri-Specific Antibody Data Accepted for ESMO 2026 Presentation

Stock News
·
Jul 20

FDA-Approved PD-L1 Test for GI Cancers Could Be A Game Changer For Agilent Technologies (A)

Simply Wall St.
·
Jul 19

Pagerduty Director Alex Shootman Files Initial Beneficial Ownership Statement

Reuters
·
Jul 16

SKB BIO's Pivotal Drug Candidate Achieves Primary Endpoint in Phase 3 Lung Cancer Trial

Stock News
·
Jul 15

Pagerduty Names Alkami CEO Alex Shootman to Board of Directors

Reuters
·
Jul 15

Pagerduty Appoints Alex Shootman to Board of Directors

THOMSON REUTERS
·
Jul 15

Agilent's PD-L1 Companion Diagnostic Receives FDA Clearance for Esophageal and Gastric Cancer Immunotherapy Selection

Deep News
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

GlobeNewswire
·
Jul 14